https://www.selleckchem.com/products/jhu395.html
001), lower rate of node-positive disease (36.6% vs. 59.8%, .001), and margin-positive resections (13.8% vs. 20.2%, .001), but slightly higher 90-day postoperative mortality (4.9% vs. 3.6%, = .04). Neoadjuvant chemotherapy+ RT was associated with longer overall survival (32.7 vs. 29.8months, = .008), and remained independently associated with survival on multivariable analysis (HR = .85, .001). In patients with stage II-III pancreatic adenocarcinoma, the addition of neoadjuvant RT to multiagent neoadjuvant CT may be associ
Like
Comment
Share
